Genmab A/S, of Copenhagen, Denmark, said partner Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, plans to start enrolling patients in a phase II study of the CD38 monoclonal antibody daratumumab in high-risk smoldering multiple myeloma next year.